The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-20 and is reviewed periodically as new material appears.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
== History == MDDMA was first described in the scientific literature by Alexander Shulgin and colleagues by 1980. Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991. The drug was described as a possible novel designer drug in 2025. David E. Olson and colleagues characterized (R)-MDDMA as a non-hallucinogenic psychoplastogen with antidepressant-like effects and improved safety relative to MDMA in 2026.
March 26 COVID-19 pandemic Maine reports its first case of the Lineage P.1 variant, which was originally detected in Brazil. Wisconsin confirms their first cases of the Lineage P.1 and 501.V2 variants of SARS-CoV-2. Arizona reports its first case of the 501.V2 variant, which was originally detected in South Africa. New Jersey amends its alcohol and cannabis laws to allow police to notify parents or guardians after a first-time offense by a minor, following strong opposition to the prohibition on first-time notifications implemented when New Jersey legalized cannabis the previous month. The U.S. Food and Drug Administration (FDA) approves Abecma to treat multiple myeloma. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. March 29 In Minnesota, opening statements begin at the trial of former police officer Derek Chauvin, who is accused of murdering 46-year-old black man George Floyd by kneeling on his neck. The Arkansas Senate passed, HB1570, a bill that prohibited normally functioning and physically healthy minors from puberty blockers, cross-sex hormones, and genital and non-genital invasive surgical alterations. A judge orders three men charged with plotting to kidnap Michigan Governor Gretchen Whitmer to stand trial, after a three-day preliminary hearing. Threat of terrorism charges are also dismissed against two of the defendants. Killing of Adam Toledo – A 13-year-old Latino boy, Adam Toledo, is shot and killed by an officer of the Chicago Police Department.
HPLC is distinguished from traditional ("low pressure") liquid chromatography because operational pressures are significantly higher (around 50–1400 bar), while ordinary liquid chromatography typically relies on the force of gravity to pass the mobile phase through the packed column. Due to the small sample amount separated in analytical HPLC, typical column dimensions are 2.1–4.6 mm diameter, and 30–250 mm length. Also HPLC columns are made with smaller adsorbent particles (1.5–50 μm in average particle size). This gives HPLC superior resolving power (the ability to distinguish between compounds) when separating mixtures in a shorter period of time, which makes it a popular chromatographic technique. The schematic of an HPLC instrument typically includes solvents' reservoirs, one or more pumps, a solvent-degasser, a sampler, a column, and a detector. The solvents are prepared in advance according to the needs of the separation, they pass through the degasser to remove dissolved gasses, mixed to become the mobile phase, then flow through the sampler, which brings the sample mixture into the mobile phase stream, which then carries it into the column. The pumps deliver the desired flow and composition of the mobile phase through the stationary phase inside the column, then directly into a flow-cell inside the detector. The detector generates a signal proportional to the amount of sample component emerging from the column, hence allowing for quantitative analysis of the sample components.
== # == 2-amino-4-deoxychorismate dehydrogenase - 2-dehydropantolactone reductase (B-specific) - 2-methylacyl-CoA dehydrogenase - 2-nitropropane dioxygenase - 2-oxobutyrate synthase - (2,3-dihydroxybenzoyl)adenylate synthase - 2,4-Dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase - 2010107G12Rik - 27-hydroxycholesterol 7alpha-monooxygenase - 3' end - 3' flanking region - 3-hydroxy-2-methylpyridinecarboxylate dioxygenase - 3-Ketosteroid 9alpha-monooxygenase - 3-oxoacyl-(acyl-carrier-protein) reductase (NADH) - (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase - 3(or 17)a-hydroxysteroid dehydrogenase - 3110001I22Rik - 3alpha-hydroxyglycyrrhetinate dehydrogenase - 4932414N04Rik - 3alpha-hydroxysteroid dehydrogenase (A-specific) - 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase - 3alpha,7alpha,12alpha-trihydroxycholestan-26-al 26-oxidoreductase - 4-Cresol dehydrogenase (hydroxylating) - 4-Hydroxycyclohexanecarboxylate dehydrogenase - 4-hydroxyphenylacetaldehyde oxime monooxygenase - 4-hydroxyphenylpyruvate oxidase - 4-Nitrophenol 4-monooxygenase - 4933425L06Rik - 5' end - 5' flanking region - 5-pyridoxate dioxygenase - 6-endo-hydroxycineole dehydrogenase - 7-deoxyloganin 7-hydroxylase - 7beta-hydroxysteroid dehydrogenase (NADP+) - 8-oxocoformycin reductase - 12beta-hydroxysteroid dehydrogenase - 25-hydroxycholesterol 7α-hydroxylase -
Ion suppression in LC-MS and LC-MS/MS refers to reduced detector response, or signal:noise as a manifested effect of competition for ionisation efficiency in the ionisation source, between the analyte(s) of interest and other endogenous or exogenous (e.g. plasticisers extracted from plastic tubes, mobile phase additives) species which have not been removed from the sample matrix during sample preparation. Ion suppression is not strictly a problem unless interfering compounds elute at the same time as the analyte of interest. In cases where ion suppressing species do co-elute with an analyte, the effects on the important analytical parameters including precision, accuracy and limit of detection (analytical sensitivity) can be extensive, severely limiting the validity of an assay's results.
Sources: en.wikipedia.org
==== PINK1, PARK7, PRKN ==== PINK1 (PARK6), PARK7 (DJ-1), and PRKN (PARK2, PARKIN) are all involved in mitochondrial activity. Mutations in these genes may cause mitochondrial dysfunction, an element of both idiopathic and familial PD. In addition, the PRKN gene encodes E3 ubiquitin ligase, which is involved in degradation of damaged proteins by ubiquitin. Many different PRKN-related mutations occur, leading to loss of protein or to protein-related loss of function. PRKN is the most common cause of autosomal-recessive PD, accounting for nearly 50% of typical early-onset parkinsonism. PRKN mutations account for 77% of juvenile PD cases. PINK1 encodes PTEN-induced putative kinase 1, and is the second-most common cause of autosomal-recessive PD. The PARK7 gene is located on chromosome 1p36 and encodes the DJ-1 protein. The DJ-1 protein is involved in cellular sensing of oxidative stress. DJ-1 related PD is rare, occurring in 0.4% - 1% of patients with early-onset PD.
CNS excitation: nervousness, agitation, anxiety, apprehension, tingling around the mouth (circumoral paraesthesia), headache, hyperesthesia, tremor, dizziness, pupillary changes, psychosis, euphoria, hallucinations, and seizures CNS depression with heavier exposure: drowsiness, lethargy, slurred speech, hypoesthesia, confusion, disorientation, loss of consciousness, respiratory depression, and apnoea. Cardiovascular: hypotension, bradycardia, arrhythmias, flushing, venous insufficiency, increased defibrillator threshold, edema, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression. Respiratory: bronchospasm, dyspnea, respiratory depression or arrest Gastrointestinal: metallic taste, nausea, vomiting, agita, and diarrhea Ears: tinnitus Eyes: local burning, conjunctival hyperemia, corneal epithelial changes/ulceration, diplopia, visual changes (opacification) Skin: itching, depigmentation, rash, urticaria, edema, angioedema, bruising, inflammation of the vein at the injection site, irritation of the skin when applied topically Blood: methemoglobinemia Allergy ADRs associated with the use of intravenous lidocaine are similar to the toxic effects of systemic exposure above. These are dose-related and more frequent at high infusion rates (≥3 mg/min). Common ADRs include headache, dizziness, drowsiness, confusion, visual disturbances, tinnitus, tremor, and/or paraesthesia.
=== Heart failure === In heart failure patients, angiotensin receptor blockers such as candesartan and valsartan may be a suitable option for those who do not tolerate angiotensin-converting enzyme inhibitor medicines. Randomised control trials have shown candesartan reduces heart failure hospitalisations and cardiovascular deaths for patients who have heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%).
Secondary structure refers to highly regular local sub-structures on the actual polypeptide backbone chain. Two main types of secondary structure, the α-helix and the β-strand or β-sheets, were suggested in 1951 by Linus Pauling. These secondary structures are defined by patterns of hydrogen bonds between the main-chain peptide groups. They have a regular geometry, being constrained to specific values of the dihedral angles ψ and φ on the Ramachandran plot. Both the α-helix and the β-sheet represent a way of saturating all the hydrogen bond donors and acceptors in the peptide backbone. Some parts of the protein are ordered but do not form any regular structures. They should not be confused with random coil, an unfolded polypeptide chain lacking any fixed three-dimensional structure. Several sequential secondary structures may form a "supersecondary unit".
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.